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Abstract
Aims/hypothesis We aimed to examine whether crude mortality and mortality relative to the general population below 50 years
of age have improved in recent years in those with type 1 diabetes.
Methods Individuals with type 1 diabetes aged below 50 and at least 1 year old at any time between 2004 and 2017 in Scotland
were identified using the national register. Death data were obtained by linkage to Scottish national death registrations. Indirect
age standardisation was used to calculate sex-specific standardised mortality ratios (SMRs). Poisson regression was used to test
for calendar-time effects as incidence rate ratios (IRRs).
Results There were 1138 deaths in 251,143 person-years among 27,935 people with type 1 diabetes. There was a significant
decline in mortality rate over time (IRR for calendar year 0.983 [95% CI 0.967, 0.998], p = 0.03), but the SMR remained
approximately stable at 3.1 and 3.6 in men and 4.09 and 4.16 in women for 2004 and 2017, respectively. Diabetic ketoacidosis
or coma (DKAoC) accounted for 22% of deaths and the rate did not decline significantly (IRR 0.975 [95% CI 0.94, 1.011], p =
0.168); 79.3% of DKAoC deaths occurred out of hospital. Circulatory diseases accounted for 27% of deaths and did decline
significantly (IRR 0.946 [95% CI 0.914, 0.979], p = 0.002).
Conclusions/interpretation Absolute mortality has fallen, but the relative impact of type 1 diabetes on mortality below 50 years
has not improved. There is scope to improve prevention of premature circulatory diseases and DKAoC and to develop more
effective strategies for enabling people with type 1 diabetes to avoid clinically significant hyper- or hypoglycaemia.
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Abbreviations
DKA Diabetic ketoacidosis
DKAoC Diabetic ketoacidosis or coma
IRR Incidence rate ratio
MCCD Medical Certificate of Cause of Death
NRS National Records for Scotland
SIMD Scottish Index of Multiple Deprivation
SMR Standardised mortality ratio
Introduction
Type 1 diabetes mellitus is associated with excess mortality
and elevated rates of mortality frommany causes, with cardio-
vascular and renal disease contributing considerably to the
excess mortality [1, 2]. There have been many advances in
cardiovascular disease prevention in the past 15 years, includ-
ing the widespread use of statin therapy in people both with
and without diabetes [3]. There is evidence of declining
cardiovascular mortality [4] and overall falls in mortality in
type 1 diabetes that are faster than in the background popula-
tion in Denmark (2002–2011) [5].
Deaths occurring below age 50 in people with type 1 diabe-
tes, although fewer in number than in older populations, have
a large impact on reduction in life expectancy. For example,
we reported that 40–45% of the overall loss in life expectancy
of 11 and 13 years in men and women with type 1 diabetes,
respectively, was attributable to deaths occurring below age
50 [1]. Whether there have been any improvements in the
prevention of these early deaths in type 1 diabetes in recent
years is uncertain, as all recent studies have been very small or
have had relatively short follow-up times, with the largest
study including 3192 individuals [6–9]. Thus, the scope for
further improvements in life expectancy by preventing such
deaths is also unknown.
To address these questions, we examined whether death
rates below age 50 years in type 1 diabetes have fallen since
2004 in a much larger dataset (n > 27,000) than previous stud-
ies. We further examined the pattern of deaths by cause and
explored the extent to which deaths are occurring out of hospi-
tal as this has important implications for preventative
strategies.
Methods
Dataset
Scottish Care Information - Diabetes (SCI-Diabetes) is the
national disease management system of individuals diagnosed
with any form of diabetes in Scotland and achieves over 99%
coverage. As described previously [1], this register can be
linked to other health record datasets including death data
provided by the Information Services Division of National
Health Service (NHS) Scotland and National Records for
Scotland (NRS). We identified a cohort of all people with a
clinical diagnosis of type 1 diabetes and who were aged below
50 years and at least 1 year old at any point during 2004–2017.
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Clinician-assigned diabetes type for each individual was
accepted unless contradictory prescription history or age-at-
diagnosis data were available (e.g. a clinician-assigned diag-
nosis of type 1 diabetes without any subsequent insulin
prescription would not be accepted) [1]. Such individuals
contributed data from 2004 or the date of their diagnosis with
type 1 diabetes, whichever was later, up to date of death
during the study period, attaining an age of 50 years, leaving
the jurisdiction or the end of the study period. Individuals
were considered to have left the jurisdiction if their electronic
health record data showed a cessation of prescriptions or atten-
dance of routine observations. Person-time below 1 year of
age was not included in the cohort so as not to introduce
immortal time bias.
The underlying cause of death was taken from the ICD10
code (http://apps.who.int/classifications/icd10/browse/2016/
en) assigned on the Medical Certificate of Cause of Death
(MCCD) issued following a death. We aggregated individual
ICD10 codes into larger groups that defined high-level body
systems or specific acute complications of diabetes. Assigning
cause-specific mortality in diabetes has a number of chal-
lenges; for example, coding rules assign diabetes as the under-
lying cause of death where myocardial infarction is recorded
on the MCCD as the underlying cause. Accordingly, when
diabetes was the underlying cause of death, but a cardiovas-
cular condition was an antecedent cause, we reassigned the
underlying cause as circulatory disease. Similarly, we placed
all deaths attributable to ‘diabetes mellitus with renal compli-
cations’ into the genitourinary system category, and all deaths
attributable to ‘diabetes with peripheral circulatory complica-
tions’ into the circulatory system category. Furthermore, it
should be noted that ICD10 coding of coma deaths does not
differentiate between ketoacidotic or hypoglycaemic coma.
Therefore, deaths due to diabetic ketoacidosis (DKA) or
hypoglycaemic or unspecified coma were placed into a single
category labelled ‘diabetic ketoacidosis or coma’ (DKAoC).
The specific assignment of individual ICD10 codes to higher-
level categories is detailed in electronic supplementary mate-
rial (ESM) Table 1.
Through linkage with NRS data we were able to identify
deaths for which a post-mortem examination had been
performed. We were also able to identify which deaths had
occurred in hospital by comparing an individual’s date of
death with their date of discharge in the hospital admission
data.
Statistical methods
Crude mortality rates were calculated by calendar year across
the entire study period and stratified by attained age band, sex
and specific cause. Indirectly standardised mortality ratios
(SMRs) were obtained by applying nationally reported overall
and cause-specific mortality rates by age and sex for the
general population to the type 1 diabetes population to esti-
mate expected deaths, against which we compared observed
deaths. Cause-specific comparisons were restricted to age
<45 years only as this was the age band cut off used in the
general population data. The area-based socioeconomic indi-
cator the Scottish Index of Multiple Deprivation (SIMD) was
used to assign the deprivation quintile to which the person
with type 1 diabetes belonged at entry. For comparison,
mortality rates stratified by SIMD quintile for the general
population during the period 2008–2013 were available from
NRS.
For presenting changes in rates over time among those with
type 1 diabetes we first compared rates for the first and second
halves of the study period, with each directly standardised to
the type 1 diabetes age and sex structure in the middle year,
i.e. 2011. In addition, Poisson regression models were used to
estimate incidence rate ratios (IRRs) per calendar year, with
2004 as the baseline year, associated with sex, SIMD and
calendar time, all adjusted by age and diabetes duration
among those with type 1 diabetes. Poisson regression was also
used to estimate IRRs for deaths by specific cause, adjusted
for the covariates outlined above. To test for changes in the
trends for all-cause and cause-specific mortality rates over
time, we applied a joinpoint regression framework [10]. This
method can identify the number and location of statistically
significant changes in mortality rate trends over time.
Results
Total mortality
Absolute total mortality rates across the period 2004–2017
There were 27,935 people diagnosed with type 1 diabetes and
aged <50 and >1 year at any point between 2004 and 2017.
The mean age of the cohort across the study period was
30.56 years, and the cohort was 44% female. There were
1138 deaths. The total follow-up time was 251,143 person-
years. The percentage of possible follow-up time that was not
observed was 2.81%. Cohort characteristics at the start and
end of the study period are presented in ESM Table 2 and
the cohort age structure over time is presented in ESM Fig.
1. As shown in Table 1, the absolute mortality rate per 100,000
person-years across the study period was 453.13 (95% CI
427.55, 480); 500.2 in men (95% CI 464.65, 538.46) and
392.54 in women (95% CI 357.18, 431.4). Across the entire
study period there were no deaths of individuals diagnosed
with type 1 diabetes in the 1–9 age band. The overall SMR
across the period was 3.42 (95%CI 3.23, 3.63). Although age-
specific absolute mortality rates were mostly lower in females
than males, SMRs at all age bands were higher for females
than males (Table 1). The highest SMR was observed in
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females aged 20–29, where there were 73 deaths compared
with 8–9 expected deaths.
Time trends in absolute total mortality and SMRs Figure 1
shows the crude mortality rates over time by sex, with no
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aFig. 1 (a) Crude mortality rate
and (b) SMR across the study
period, stratified by sex. Points
and bars for each year are slightly
staggered to enhance visibility.
Error bars show 95% CI. F,
female; M, male
Table 1 Deaths and excess
deaths stratified by age band and
sex across the entire study period
Age Sex N Person-
Years
Crude Ratea Expected N SMR (95% CI)
1–9 F 0 5156.11 0.00 0.58 –
1–9 M 0 5546.94 0.00 0.81 –
10–19 F 19 20,511.44 92.63 3.78 5.03 (3.21, 7.89)
10–19 M 28 22,754.83 123.06 7.50 3.73 (2.58, 5.41)
20–29 F 73 25,016.61 291.82 8.75 8.34 (6.63, 10.49)
20–29 M 83 32,577.34 254.78 30.55 2.72 (2.19, 3.37)
30–39 F 128 27,847.34 459.65 23.02 5.56 (4.68, 6.61)
30–39 M 220 37,280.00 590.13 65.03 3.38 (2.96, 3.86)
40–49 F 211 31,267.49 674.82 57.14 3.69 (3.23, 4.23)
40–49 M 376 43,187.42 870.62 135.51 2.77 (2.51, 3.07)
Total M+F 1138 251,143.52 453.13 332.68 3.42 (3.23, 3.63)
Total F 431 109,798.99 392.54 93.27 4.62 (4.20, 5.08)
Total M 707 141,345.53 500.20 239.41 2.95 (2.74, 3.18)
a Crude rate is expressed per 100,000 person-years
F, female; M, male
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obvious trend discernible against the variation year to year.
However, in the first half of the study period the total mortality
rate (directly standardised to the 2011 age and sex distribution
in those with type 1 diabetes) was 474.14 per 100,000 person-
years (95% CI 468.58, 479.71) compared with 441.07 (95%
CI 435.86, 446.28) in the second half. When calendar year
was modelled as a categorical variable, a likelihood ratio test
against the null model supported heterogeneity in yearly
mortality rates (p = 0.002). Using Poisson regression to test
for any linear effect of calendar time among those with type
1 diabetes, adjusted for age, sex and diabetes duration, there
was a significant reduction in mortality with time (IRR per
year 0.983 [95% CI 0.967, 0.998], p = 0.03). Joinpoint regres-
sion did not identify a significant shift in the trend for directly
standardised mortality rate over time (p = 0.062). Sex-
stratified analyses found broadly similar point estimates for
calendar time for males (IRR 0.985 [95% CI 0.965, 1.004])
and females (IRR 0.979 [95% CI 0.954, 1.004]). Similar point
estimates for calendar-time effect were observed in those
below age 30 vs those aged 30 or older (IRR 0.964 [95% CI
0.930, 1.000]; IRR 0.988 [95% CI 0.971, 1.005]).
During this period, mortality rates in the general population
aged 1–49 years in Scotland also declined to a broadly similar
extent (IRR for the effect of calendar time 0.987 [95% CI
0.985, 0.989], p < 0.001). Accordingly, there was no improve-
ment in the SMR associated with diabetes (Fig. 1), going from
3.10 (95% CI 2.36, 4.07) to 3.60 (95% CI 2.81, 4.60) in males
and 4.09 (95% CI 2.78, 6.01) to 4.16 (95% CI 2.88, 6.03) in
females in 2004–2017. Similarly, joinpoint regression identi-
fied no significant shift in the SMR over time for males (p =
0.086) or females (p = 0.19).
The association of social deprivation with total mortality We
have previously reported large socioeconomic differences in
achievement of glucose control in type 1 diabetes in our popu-
lation [11]. Accordingly, among those with type 1 diabetes we
explored the association of total mortality with social depriva-
tion, adjusted for age, sex and diabetes duration. As age-, sex-
and SIMD-specific mortality rates were available for the
general population, we were also able to compute SIMD
quintile-specific SMRs.
Among those with type 1 diabetes, mortality varied strong-
ly with SIMD quintile, with the IRR for the fifth living in the
most-deprived vs the fifth living in the least-deprived quintile
being 4.89 (95% CI 3.77, 6.43). IRRs for each SIMD quintile
relative to the least-deprived quintile are presented in ESM
Fig. 2. The effect appeared linear as the IRR for SIMD as a
continuous term was 1.47 (95% CI 1.40, 1.54) with a p value
of <0.001, so that risk escalated with each SIMD group. There
was no evidence of any change in SIMD effects over time
(SIMD×time interaction term in the Poisson model p values
>0.188 for all quintiles). However, the SMR associated with
diabetes compared with the background population was
similar across SIMD quintiles (Fig. 2). Thus, while there are
strong associations of deprivation with total mortality among
those with type 1 diabetes, these are of a similar magnitude to
the association of SIMD with mortality in the background
population and have not changed over this period.
Cause-specific mortality
Cause of death by age Due to a lack of underlying cause for
approximately 30 deaths that occurred in 2017 for which post-
mortem results are pending, we excluded all data from this
year when performing calculations and tabulations for cause-
specific mortality.
Overall, 57% of deaths (n = 654: 81% of deaths out of
hospital and 26% of deaths in hospital) had a post-mortem
examination. Altogether, there were 188 deaths for which
DKA was the underlying cause and one with hypoglycaemia
as the underlying cause. There were 48 deaths that had the
ICD10 code for ‘diabetes with coma’ as the underlying cause,
of which zero had hypoglycaemia as a secondary cause and
zero had DKA as a secondary cause. So, for 48 deaths it is
unclear whether the coma was due to DKA or hypoglycaemia.
We therefore used a combined term of ‘DKAoC’ to encom-
pass all deaths due to either DKA or hypoglycaemia.
Of the 1047 deaths in the study period prior to 2017, the
most common were circulatory system deaths (27%), follow-
ed by deaths due to DKAoC (22%) and external causes of
mortality (9%). As shown in Table 2, the absolute rate of each
cause rises with age, but most steeply so for circulatory
disease and neoplasm deaths.
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Fig. 2 SMR by SIMD quintile and sex (2008–2013 only). The horizontal
dotted line marks an SMR of 1. Error bars show 95% CI. F, female; M,
male
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Table 2 Mortality and excess mortality stratified by specific cause and age band 2004–2016
Cause of death Age N (N < 45) Crude rate (95% CI)a SMR (95% CI)b Proportion with
post-mortem
Proportion in
hospital
Certain infectious and parasitic diseases 15–24 – 1.86 (0.26, 13.2) 4.67 (0.66, 33.16) 0.00 1.00
Certain infectious and parasitic diseases 25–34 – 5.01 (1.62, 15.54) 4.39 (1.41, 13.6) 0.67 0.67
Certain infectious and parasitic diseases 35–44 – 18.09 (10.5, 31.15) 6.01 (3.49, 10.36) 0.23 0.85
Certain infectious and parasitic diseases 45–49 – 10.84 (4.07, 28.87) – 0.00 1.00
Certain infectious and parasitic diseases Total 21 (17) 8.36 (5.45, 12.82) 5.37 (3.34, 8.64) 0.24 0.86
DM other 15–24 – 14.88 (7.44, 29.75) – 0.88 0.12
DM other 25–34 – 28.4 (17.65, 45.68) – 0.76 0.29
DM other 35–44 – 50.09 (36.13, 69.45) – 0.58 0.28
DM other 45–49 – 37.93 (22.46, 64.04) – 0.57 0.43
DM otherc Total 75 (61) 29.86 (23.82, 37.45) – 0.65 0.29
DM with DKAoC 10–14 – 16.64 (5.37, 51.6) – 0.33 1.00
DM with DKAoC 15–24 – 87.4 (65.67, 116.33) – 0.87 0.30
DM with DKAoC 25–34 – 101.9 (79.29, 130.97) – 0.87 0.13
DM with DKAoC 35–44 – 121.06 (98.12, 149.37) – 0.86 0.20
DM with DKAoC 45–49 – 94.82 (68.08, 132.07) – 0.86 0.17
DM with DKAoC Total 233 (198) 92.78 (81.6, 105.49) – 0.86 0.21
Diseases of the circulatory system 15–24 – 11.16 (5.01, 24.84) 5.98 (2.69, 13.31) 0.67 0.83
Diseases of the circulatory system 25–34 – 58.47 (41.98, 81.43) 8.84 (6.34, 12.31) 0.66 0.49
Diseases of the circulatory system 35–44 – 197.59 (167.62, 232.92) 6.76 (5.73, 7.96) 0.47 0.57
Diseases of the circulatory system 45–49 – 276.34 (227.6, 335.53) – 0.41 0.43
Diseases of the circulatory system Total 285 (183) 113.48 (101.04, 127.45) 7 (6.06, 8.1) 0.48 0.52
Diseases of the digestive system 15–24 – 1.86 (0.26, 13.2) 3.04 (0.43, 21.58) 1.00 1.00
Diseases of the digestive system 25–34 – 10.02 (4.5, 22.31) 1.99 (0.89, 4.43) 0.50 0.50
Diseases of the digestive system 35–44 – 40.35 (28.04, 58.07) 1.94 (1.35, 2.79) 0.52 0.45
Diseases of the digestive system 45–49 – 46.06 (28.63, 74.09) – 0.24 0.88
Diseases of the digestive system Total 53 (36) 21.1 (16.12, 27.62) 1.96 (1.41, 2.72) 0.43 0.60
Diseases of the genitourinary system 25–34 – 20.05 (11.38, 35.3) 55.07 (31.28, 96.98) 0.25 0.42
Diseases of the genitourinary system 35–44 – 59.83 (44.37, 80.68) 68.59 (50.87, 92.49) 0.21 0.79
Diseases of the genitourinary system 45–49 – 40.64 (24.5, 67.41) – 0.13 0.80
Diseases of the genitourinary system Total 70 (55) 27.87 (22.05, 35.23) 61.44 (47.17, 80.02) 0.20 0.73
Diseases of the nervous system 10–14 – 5.55 (0.78, 39.38) 4.16 (0.59, 29.53) 0.00 1.00
Diseases of the nervous system 15–24 – 7.44 (2.79, 19.82) 2.5 (0.94, 6.65) 0.25 1.00
Diseases of the nervous system 25–34 – 11.69 (5.57, 24.53) 3.52 (1.68, 7.38) 0.57 0.57
Diseases of the nervous system 35–44 – 15.31 (8.48, 27.64) 2.77 (1.53, 5) 0.18 0.73
Diseases of the nervous system 45–49 – 18.96 (9.04, 39.78) – 0.29 1.00
Diseases of the nervous system Total 30 (23) 11.95 (8.35, 17.08) 2.89 (1.92, 4.35) 0.30 0.80
Diseases of the respiratory system 15–24 – 3.72 (0.93, 14.87) 3.64 (0.91, 14.56) 0.50 0.50
Diseases of the respiratory system 25–34 – 3.34 (0.84, 13.36) 1.8 (0.45, 7.19) 0.00 1.00
Diseases of the respiratory system 35–44 – 13.91 (7.49, 25.86) 2.4 (1.29, 4.46) 0.60 0.70
Diseases of the respiratory system 45–49 – 32.51 (18.46, 57.25) – 0.17 0.67
Diseases of the respiratory system Total 26 (14) 10.35 (7.05, 15.21) 2.31 (1.37, 3.9) 0.35 0.69
External causes of mortality 10–14 – 5.55 (0.78, 39.38) 2.09 (0.29, 14.82) 1.00 1.00
External causes of mortality 15–24 – 27.89 (16.82, 46.27) 1.01 (0.61, 1.68) 0.93 0.27
External causes of mortality 25–34 – 50.12 (35.04, 71.68) 1.14 (0.8, 1.64) 0.97 0.13
External causes of mortality 35–44 – 50.09 (36.13, 69.45) 0.93 (0.67, 1.29) 0.86 0.19
External causes of mortality 45–49 – 32.51 (18.46, 57.25) – 0.83 0.25
External causes of mortalityd Total 94 (82) 37.43 (30.58, 45.81) 1.02 (0.82, 1.27) 0.90 0.20
Mental and behavioural disorders 15–24 – 5.58 (1.8, 17.3) 1.35 (0.44, 4.19) 1.00 0.33
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As shown in Fig. 3, below 30 years of age DKAoC deaths
account for almost half the deaths (43%), whereas above this
age they account for 18%. Of note is that 79% of DKAoC
deaths occurred out of hospital. As with total mortality,
DKAoC death rates varied by SIMD, with IRR for the most-
vs least-deprived quintile 11.324 (95% CI 5.398, 29.074; p<
0.001); there were seven DKAoC deaths in the least-deprived
quintile compared with 88 in the most-deprived quintile.
Cause-specific SMRs For causes of death other than those
coded as diabetes, the age-standardised cause-specific SMRs
are shown in Table 2 and Fig. 4. Cause-specific SMRs by age
band are presented in ESM Fig. 3. There was a significant
elevation in deaths, and not just circulatory and renal system
deaths, as expected, but also infectious deaths and digestive,
nervous and respiratory system deaths, as well as mental and
behavioural deaths in women. Digestive system deaths mostly
comprised alcoholic liver disease deaths (42%). Genitourinary
deaths mostly comprised renal deaths (89%). For diseases of
the nervous system the most frequent cause was epilepsy
(37%). Diseases of the respiratory system mostly comprised
pneumonia (38%). Mental and behavioural deaths mostly
comprised alcohol or opioid dependence deaths (70%). The
most common neoplasms were breast (16%) and lung (16%).
External causes mostly comprised intentional and accidental
poisoning (62%). The SMRs were larger in females than
males for most cause categories.
Cause-specific rates over timeWe examined time trends in the
twomost common causes of death. In the first half of the study
period the rate of deaths caused by DKAoC per 100,000
person-years (directly standardised to the 2011 age distribu-
tion in those with type 1 diabetes) was 104.65 (95% CI
102.04, 107.26), compared with 96.39 (95% CI 93.32,
99.45) in the second half. There was minimal support for
heterogeneity in the rate of DKAoC mortality across the study
period (p = 0.12). Using Poisson regression adjusted for age,
diabetes duration and sex to test for a linear time trend for
deaths caused by DKAoC showed no significant downward
trend (IRR per year 0.975 [95% CI 0.94, 1.011], p = 0.168).
When the same Poisson regression model was applied with
the outcome variable redefined to consist only of deaths with a
definite underlying cause of DKA, then there was still no
evidence of a significant downward trend over time (IRR
per year 1.007 [95% CI 0.966, 1.049], p = 0.74). Similarly,
joinpoint regression did not identify a significant shift in the
trend of the rate of DKAoC mortality over time (p = 0.33).
There were too few definite hypoglycaemia deaths to analyse
separately.
In the first half of the study period the rate of deaths caused
by diseases of the circulatory system per 100,000 person-years
(directly standardised to the 2011 age distribution in those
with type 1 diabetes) was 131.47 (95% CI 128.53, 134.41),
compared with 116.51 (95% CI 113.13, 119.89) in the second
half. Of the individuals with type 1 diabetes and a cause of
Table 2 (continued)
Cause of death Age N (N < 45) Crude rate (95% CI)a SMR (95% CI)b Proportion with
post-mortem
Proportion in
hospital
Mental and behavioural disorders 25–34 – 15.03 (7.82, 28.9) 1.23 (0.64, 2.36) 1.00 0.00
Mental and behavioural disorders 35–44 – 23.66 (14.71, 38.05) 1.52 (0.95, 2.45) 0.82 0.12
Mental and behavioural disorders 45–49 – 21.67 (10.84, 43.34) – 0.50 0.50
Mental and behavioural disorders Total 37 (29) 14.73 (10.67, 20.33) 1.4 (0.97, 2.01) 0.81 0.19
Neoplasms 15–24 – 3.72 (0.93, 14.87) 1.07 (0.27, 4.28) 0.50 0.50
Neoplasms 25–34 – 16.71 (8.99, 31.05) 1.84 (0.99, 3.41) 0.00 0.70
Neoplasms 35–44 – 36.18 (24.63, 53.14) 1.17 (0.79, 1.71) 0.04 0.73
Neoplasms 45–49 – 113.79 (84.09, 153.97) – 0.02 0.67
Neoplasms Total 80 (38) 31.85 (25.59, 39.66) 1.26 (0.91, 1.72) 0.04 0.69
Other 15–24 – 11.16 (5.01, 24.84) – 0.50 0.50
Other 25–34 – 23.39 (13.85, 39.49) – 0.71 0.43
Other 35–44 – 25.05 (15.78, 39.75) – 0.78 0.28
Other 45–49 – 13.55 (5.64, 32.55) – 1.00 0.60
Othere Total 43 (38) 17.12 (12.7, 23.09) – 0.74 0.40
a Crude mortality rate is expressed per 100,000 person-years
b SMR calculations are restricted to individuals less than 45 years old due to restricted availability of data in the general population
c ‘DM other’ consists of ICD10 codes for any form of diabetes with ‘unspecified complications’, ‘no complications’ or ‘multiple complications’
d ‘External causes of mortality’ consists of ICD10 codes V01–Y98
e ‘Other’ consists of ICD10 codes D50–89, L00–99, M00–99, O00–99, P00–99, R99 and Q00–99
DM, type 1 diabetes mellitus
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death attributable to diseases of the circulatory system, 55%
had a previous hospitalisation for either hypertensive disease
or ischaemic heart disease at any point in time, 86% had ever
received a prescription for any cardiovascular drug and 70%
had ever received a prescription for any statin. SMRs for
diseases of the circulatory system were 9.78 (95% CI 6.31,
15.16) in 2004 and 6.98 (95% CI 3.97, 12.3) in 2016. Using
Poisson regression adjusted for age, diabetes duration and sex
to test for a linear time trend for deaths caused by diseases of
the circulatory system resulted in an IRR per year of 0.946
(95% CI 0.914, 0.979; p = 0.002); in the general population
the age band- and sex-adjusted effect of calendar time on
circulatory disease mortality was 0.970 (95% CI 0.961,
0.978; p < 0.001). Joinpoint regression did not identify a
significant shift in the trend of the rate of circulatory disease
mortality over time (p = 0.24).
Discussion
Key findings
This is one of the largest investigations of deaths under age
50 years in type 1 diabetes that has been conducted in recent
years. We have deliberately focused on this age range because
analyses focusing on the total population are primarily deter-
mined by circulatory system and cancer deaths at older ages,
and patterns at younger ages are therefore often obscured. Yet
deaths under age 50 account for half of all the total loss in life
expectancy associated with type 1 diabetes [1], and the strat-
egies needed to tackle this are somewhat different from those
for reducing death rates at older ages. The key findings from
our study are that between 2004 and 2017 there was an
improvement in the absolute mortality rate under age 50 years,
but that relative mortality showed no sign of improvement,
with rates remaining between three- and fourfold higher
among people with type 1 diabetes than the general popula-
tion. SMRs were markedly higher in females than males.
There was no clear evidence that the rate of DKAoC deaths
fell, and the absolute rate remains high, with approximately 80
deaths per 100,000 population per year. Most of these deaths
occur out of hospital. Rates of circulatory deaths, the most
common cause of death, have fallen in this period, but not
significantly more so than reductions in deaths from this cause
in the background population. Death rates are elevated not just
for the causes commonly recognised as diabetes complica-
tions (diabetes specific, circulatory and renal) but also for
infectious diseases and diseases of the respiratory, digestive
and nervous systems, demonstrating the impact of type 1
diabetes across all body systems. An ongoing large socioeco-
nomic differential in death rates among people with type 1
diabetes has persisted across the period. For overall mortality
rates these are of similar magnitude as socioeconomic differ-
entials in the background population. However, for DKAoC
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deaths there was a disturbing 11-fold difference in the rates in
the most- vs least-deprived quintiles of the population.
Comparison with past literature
High SMRs at young ages in diabetes have been reported in
other countries, but changes in absolute and relative mortality
rates compared with the background population over time
vary between studies. Studies in Australia (2000–2011),
Finland (1970–1999) and Denmark (2002–2011) identified
reductions in both absolute and relative mortality rates, where-
as analyses in Sweden (1998–2011), Wales and Northern
Ireland (1989–2012) found no improvement in relative
mortality [2, 5–7, 12–14].
The greater relative effect of diabetes on CVD, renal
disease, neoplasms, and accident and suicide in females than
in males has been reported elsewhere [15]; here, we show that
this greater effect of diabetes in females extends to other body
systems, including respiratory disease and infectious disease
deaths. We note poorer glycaemic control in females than
males in our population [11], which is an observation made
in other national populations of people with type 1 diabetes
[16]. It has long been debated whether this reflects a biological
or behavioural phenomenon [17], and we are not aware of any
interventions that have been shown to alter it. Clearly, such
exploratory and intervention studies are needed if we are to
reduce this disparity in diabetes effect by sex.
Strengths and limitations
Strengths of our work are the large size of the dataset
enabling precise estimates of rates and effects. The limi-
tations of our study mostly pertain to generalisability
since our analysis has only been carried out within one
country. Another limitation is that routine datasets have
limitations in how extensively they can explore specific
circumstances leading to death. Such detailed individual
scrutiny of deaths, as is done, for example, in a confiden-
tial inquiry methodology, may be the most useful for
informing preventative policies for DKA and coma
deaths.
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Policy implications and conclusions
The lack of improvement in relative mortality and the persis-
tent socioeconomic differential in this nationwide analysis
emphasise the profound need to improve the lives of those
with type 1 diabetes and to ensure that advances in care reach
all sectors of society. In Scotland in the past decade or so there
have been regularly renewed strategic plans to improve diabe-
tes management in our national health system, including more
widespread psychological support, improved access to struc-
tured education and widening of access to pumps, continuous
glucose monitoring and flash glucose monitors. Yet, despite
this, these theoretically preventable early deaths continue to
occur. There has been no significant improvement in the rate
of DKA and coma deaths and clearly more work needs to be
done to achieve this. Our analysis shows that these deaths are
not occurring through poor hospital management or poor inpa-
tient care of those with glycaemic crises—most of the deaths
occur out of hospital. This implies a need for greater education
and preventative strategies targeted at people with diabetes,
their peers and their families. Currently, all people with type 1
diabetes in Scotland receive education on insulin management
during sickness and are provided with meters for measuring
ketones. In addition, education is provided on the avoidance
of hypoglycaemia as well as the impact of recreational drug
use and alcohol. A previous analysis from one health board
found that over 50% of DKA admissions are from individuals
who have experienced two or more DKA events, and such
individuals have a high risk of subsequent mortality [18].
This suggests that more intensive management of individuals
after DKA is required. Of particular concern is the large socio-
economic differential in these deaths. It will be critically
important to ensure that new strategies for use of pumps and
blood glucose-monitoring devices reduce rather than widen
this differential. It is also essential that pump therapy is intro-
duced safely as these devices have been shown to increase the
risk of acute metabolic complications in individuals with
lower socioeconomic status [19]. With regard to the ongoing
excess of circulatory deaths, the high rate of prior
hospitalisation and prescriptions for hypertensive and ischae-
mic heart conditions suggests that the majority of these deaths
are occurring in individuals with established circulatory
disease rather than sudden deaths in people with no prior
history. Our further work is focusing on building prediction
models of those most at risk so that preventative strategies
can be tailored to those at risk. Although the relative
mortality rates for circulatory diseases are high, the abso-
lute mortality rates are not, e.g. <5% 5 year mortality risk
in the 45–49 age group (Table 2). In addition to targeted
preventative strategies, population-level improvements in
smoking cessation, glycaemic control, and blood pressure
and lipid management are needed to drive this rate down
further. The occurrence of renal disease deaths at a young
age against a backdrop of national policies on annual
albumin/creatinine ratio and eGFR checks and risk factor
monitoring is also disturbing. We have learned a great deal
about prevention of diabetes complications in recent
decades, but many people with type 1 diabetes continue
to experience a profound impact on health. There is no
room for complacency. We need further initiatives to
predict, identify and provide support to those most at risk
of premature mortality from type 1 diabetes.
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